Terms: = Leukemia AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10 AND Treatment
159 results:
1. Myelodysplastic Neoplasms (MDS): The Current and Future treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract] [Full Text] [Related]
2. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
4. Chronic Lymphocytic leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing.
Grants JM; May C; Bridgers J; Huang S; Gillis S; Meissner B; Boyle M; Ben-Neriah S; Hung S; Duns G; Hilton L; Gerrie AS; Marra M; Kridel R; Sabatini PJB; Steidl C; Scott DW; Karsan A
Clin Chem; 2024 Jan; 70(1):273-284. PubMed ID: 38175592
[TBL] [Abstract] [Full Text] [Related]
5. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
[TBL] [Abstract] [Full Text] [Related]
6. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
[TBL] [Abstract] [Full Text] [Related]
7. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.
Xian RR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):51-58. PubMed ID: 38066895
[TBL] [Abstract] [Full Text] [Related]
8. Next-generation therapy for lower-risk MDS.
Sébert M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
[TBL] [Abstract] [Full Text] [Related]
9. Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.
Navrkalova V; Plevova K; Radova L; Porc J; Pal K; Malcikova J; Pavlova S; Doubek M; Panovska A; Kotaskova J; Pospisilova S
Br J Haematol; 2024 Jan; 204(1):240-249. PubMed ID: 38062779
[TBL] [Abstract] [Full Text] [Related]
10. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
11. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo RD; Iqbal M; Von Roemeling R; Von Roemeling C; Tun HW
Front Immunol; 2023; 14():1239082. PubMed ID: 37954584
[TBL] [Abstract] [Full Text] [Related]
12. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
13. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract] [Full Text] [Related]
14. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Haque T; Cadenas FL; Xicoy B; Alfonso-Pierola A; Platzbecker U; Avivi I; Brunner AM; Chromik J; Morillo D; Patel MR; Falantes J; Leitch HA; Germing U; Preis M; Lenox L; Lauring J; Brown RJ; Kalota A; Mehta J; Pastore F; Gu J; Mistry P; Valcárcel D
Leuk Res; 2023 Nov; 134():107390. PubMed ID: 37776843
[TBL] [Abstract] [Full Text] [Related]
15. Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP; Germing U; Malcovati L
Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
[TBL] [Abstract] [Full Text] [Related]
16. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
17. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.
Hogg G; Severson EA; Cai L; Hoffmann HM; Holden KA; Fitzgerald K; Kenyon A; Zeng Q; Mooney M; Gardner S; Chen W; Nagan N; Boles D; Parker S; Richman TJ; Letovsky S; Dong H; Anderson SM; Ramkissoon S; Reddy P; Eisenberg M; Chenn A; Jensen TJ
Cancer Genet; 2023 Nov; 278-279():38-49. PubMed ID: 37586297
[TBL] [Abstract] [Full Text] [Related]
18. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract] [Full Text] [Related]
19.
Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of hypereosinophilia in a case of
Martinez-Gutierrez LN; Burgher BC; Glynias MJ; Alvarado D; Griffiths EA; Glenn ST; Sung PJ
Cold Spring Harb Mol Case Stud; 2023 Jun; 9(3):. PubMed ID: 37433680
[TBL] [Abstract] [Full Text] [Related]
[Next]
